Current Understanding of Myeloproliferative Neoplasm-Related Gene Mutations and Cytokine -Review.
10.7534/j.issn.1009-2137.2018.02.047
- Author:
Zhi-Peng HE
1
,
2
;
Yong WU
1
,
3
Author Information
1. Department of Hematology, Union Hospital, Fujian Medical University
2. Fujian Key Laboratory of Hematology, Fujian Institute of Hematology,Fuzhou 350001,Fujian Province,China.
3. Fujian Key Laboratory of Hematology, Fujian Institute of Hematology,Fuzhou 350001,Fujian Province,China. E-mail: wuyong9195@126.com.
- Publication Type:Journal Article
- MeSH:
Calreticulin;
Cytokines;
Humans;
Janus Kinase 2;
Mutation;
Myeloproliferative Disorders;
Thrombocythemia, Essential
- From:
Journal of Experimental Hematology
2018;26(2):589-594
- CountryChina
- Language:Chinese
-
Abstract:
Myeloproliferative neoplasm(MPN) is clonal hematopoietic stem cell disorder characterized by abnormal proliferation and expansion of one or more myeloid lineages. BCR-ABL-negative MPN includes polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The mutations of JAK2, CALR and MPL genes are involved in the pathogenesis of MPN that provided a more complete molecular diagnostic standard for MPN. More and more new mutated genes related to prognosis of MPN were discovered in the past few years, at same time it was found that cytokines were also involved in the genesis and development of MPN. These provide a theoretical basis for the diagnosis, risk stratification and treatment management of MPN. In this article, the mechanisms of MPN-related cytokines and mutated genes in the genesis and development of disease and prognosis characteristics are summarized.
